本文へ移動
cccskills
無料GitHub で公開

es-cushing-against-treatment-no-diagnosis

This skill recommends against initiating cortisol-lowering treatment when there is no established diagnosis of Cushing's syndrome. It is triggered when a clinician considers treating suspected CS based only on borderline biochemical abnormalities or nonspecific signs without confirmatory testing; examples include "suspected CS", "borderline UFC", "no confirmed diagnosis", "consider empiric ketoconazole".

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Against Treatment Without Established Cushing's Syndrome Diagnosis

STEP 1 — Gather Information

Collect history of CS signs (central obesity, facial plethora, proximal muscle weakness, easy bruising, violaceous striae) and symptoms (hypertension, diabetes, osteoporosis, psychiatric changes). Perform initial biochemical screening: 24‑h urine free cortisol, late‑night salivary cortisol, or 1‑mg overnight dexamethasone suppression test. Note any cyclic patterns; do not rely on a single borderline result.

STEP 2 — Rule In / Rule Out

Is there an established diagnosis of Cushing's syndrome confirmed by at least two abnormal biochemical tests or one abnormal test with typical clinical features?

  • YES → Proceed to treatment planning.
  • NO → Do not start cortisol‑lowering therapy.

STEP 3 — Classify or Stratify

When diagnosis is not established, determine whether specific CS signs/symptoms are present.

  • Specific signs/symptoms present → Pursue further diagnostic workup (repeat testing, dexamethasone‑CRH test, inferior petrosal sinus sampling) before considering treatment.
  • Only borderline biochemical abnormality without specific signs → Recommend against treatment and observe or repeat testing.

STEP 4 — Decide

Do not initiate medication, surgery, or radiation aimed at lowering cortisol. Instead, arrange follow‑up biochemical testing in 3–6 months, evaluate for cyclic CS, and treat comorbidities (e.g., hypertension, diabetes) with standard therapies.

Clinical Guardrails / Mimics / Pitfalls

Do not treat based on a single borderline UFC or late‑night salivary cortisol; avoid empiric ketoconazole, metyrapone, or mifepristone without confirmed CS, as this can cause iatrogenic adrenal insufficiency. Recognize that isolated hypertension or diabetes may mimic CS but require standard management. Beware of cyclic CS where a single normal test does not exclude disease.

Concrete Clinical Example

A 45‑year‑old woman with mild hypertension and a UFC 1.2× upper limit of normal (borderline) but no facial plethora, proximal weakness, or striae considers starting ketoconazole. The skill advises against treatment, recommends repeat UFC and late‑night salivary cortisol in 1 month, and to manage hypertension with an ACE inhibitor pending clarification.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI: 10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する